Background {#Sec1}
==========

Acute-on-chronic liver failure (ACLF) occurs when liver function is suddenly compromised as a result of an incident \[[@CR1]\]. In 2009, the Asia-Pacific Association for the Study of the Liver (APASL) recommended the following definition for ACLF: acute hepatic damage showing coagulopathy and jaundice, with encephalopathy and/or ascites within 4 weeks, whether or not the patient had been diagnosed with a chronic liver disease \[[@CR2]\]. The majority of Chinese ACLF patients showed HBV-induced hepatitis \[[@CR3], [@CR4]\]. Although the biological pathways that mediate HBV infection and cause liver failure remain unknown, studies suggest that mutations in the HBV viral genome may play a role in the progression of liver diseases \[[@CR5]--[@CR8]\]. HBV mutations in the basal core promoter (BCP)/pre-core (PC) regions are relatively well understood \[[@CR9]--[@CR11]\]. BCP mutations lead to enhanced HBV replication in vitro, while PC mutations break the immune tolerance of chronic HBV infection by inhibiting hepatitis B e antigen (HBeAg) translation \[[@CR9]--[@CR11]\]. Therefore, it is important to better understand the relationship between HBV mutations and ACLF, which may have clinical utility. Several studies have shown that HBV mutations in the BCP or PC regions are related to the risk of ACLF, although the sample size and the mutational sites tested were limited. Therefore, we performed a meta-analysis to quantitatively evaluate data from several available studies and investigated the relationship between HBV BCP/PC variations and the risk of developing ACLF.

Results {#Sec2}
=======

Search results {#Sec3}
--------------

We identified 2790, 831, 25 and 15 articles from the PubMed, EMbase, Biomed Central and ClinicalTrials databases, respectively. The four primary Chinese databases used were: Chinese Biological Medicine, WANFANG DATA, VIP and China National Knowledge Infrastructure, which yielded 889, 1564, 1011 and 1303 studies, respectively. This approach resulted in 3478 and 2203 studies after removing duplicates from English and Chinese databases, respectively. After title screening (4908 not relevant to HBV mutation or liver failure, 310 associated with human immunodeficiency virus (HIV) or hepatitis C virus), 463 potential articles remained, which were reduced to 61 after reviewing abstracts (338 were not related to mutations, 35 not related to ACLF and 29 related to hepatocellular carcinoma \[HCC\]). In addition, 30 articles were removed after completing a full text scan (17 lacked control groups, 5 participants were co-infected with other hepatic viruses, 2 were co-infected with HIV and 6 had HCC). We included 31 articles in our meta-analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of article selection

Characteristics of trials included in this meta-analysis {#Sec4}
--------------------------------------------------------

The 31 trials were all case--control trials from China. The primary mutation detection method was nested polymerase chain reaction and sequencing. The quality of the studies on the Newcastle-Ottawa Scale (NOS) scale was between 5 and 7 (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). There were 5817 HBV patients, 1995 of whom had ACLF. The most common mutations in the BCP/PC regions that were associated with ACLF progression were T1753V, A1762T/G1764A, A1762T, G1764A, C1766T, T1768A, A1846T, G1862T, G1896A, G1899A and G1896A/A1762T/G1764A (Table [1](#Tab1){ref-type="table"}).Table 1Main characteristics of included trialsStudyNCANCOMutation siteDetection methodMatching factorsAgeSexGenotypeHBV DNAAiming Zhang, 20132952T1753V, A1762T, G1764A, A1762T/G1764A, A1846T, G1896A, G1899ANP, AS++++Aiming Zhang2, 20135851T1753V, A1762T, G1764A, A1762T/G1764A, A1846T, G1896A, G1899ANP, AS++++Lei Xiao, 201377136T1753V, A1762T/G1764A, C1766T, T1768A, A1846T, G1862T, G1896A, G1899ANP, AS++\--Xiaodong Li, 2013146239T1753V, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899ANP, AS++\--X Ren, 2010 (40)75328T1753V, A1762T, G1764A, C1766T, T1768A, G1896A, G1899ANP, AS++++Zhihui Xu, 2010298495T1753V, A1762T, G1764A, C1766T, T1768A, G1862T, G1896A, G1899ANP, AS+++-Ling Yang, 20103944A1762T/G1764A, G1862T, G1896A, G1899ASNP, AS-++-Zhengang Zhao, 20102019T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1862T, G1896A, G1899A, A1762T/G1764A/G1896ANP, DS-++-Xiaoyan Ma, 20124428T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899A, A1762T/G1764A/G1896ANP, S-++-Zhiwei Li, 20021310A1846T, G1862T, G1896ARP, SANDNDND-Shoubing Tang, 20053030A1762T/G1764A, G1896ARP, CS++ND-Yintang Jia, 2009878T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899ANP, DSNDNDND-Ling Jiang, 2013146239A1762T/G1764A, G1896AQPMK, DS++ND-Wenjun Du, 2005975A1762T, G1764A, G1896ARP, GC, SNDNDND-Xiumei Zhou, 20098080A1762T/G1764A, G1896A, G1899ARP, GC++ND-Mingxian Zhou, 20042256A1762T, G1896AUKNDND+-Xiaoqiang Ren, 2009348610T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, G1862T, G1896A, G1899A, A1762T/G1764A/G1896ANP, AS+++-Lei Jiang, 20102678G1896ANP, RFLPNDNDND-Jinqiang Li, 20063020A1762T/G1764A, G1896ARP, MS++ND-Chengyong Liu, 200734186A1762T/G1764A, G1896A, A1762T/G1764A/G1896ARP, MGSNDNDND-Xinyu Liu, 20051475A1762T, G1764A, A1762T/G1764A, G1896A, A1762T/G1764A/G1896ALASNDNDND-Shuren Liang, 20032368G1896ARP, OASND+ND-Zhidong Zang, 20071781A1762T/G1764ARP, LASNDNDND-Tao Yan, 20104945T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899A, A1762T/G1764A/G1896ANP, AS-++-Wei Guo, 20063840T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, G1862T, G1896A, G1899A, A1762T/G1764A/G1896ARP, CS++ND-Yanhong Yu, 20082598A1762T/G1764ARP, GCNDNDND-Guanghui Wu, 20083030A1762T/G1764A, G1896ARP, RFLPND++-Hangdi Xu, 20131212A1762T, G1764A, A1846T, G1896ARP, IS++++Fan Li, 2008 (31)87196T1753V, A1762T, G1764A, G1862T, G1896A, G1899ANP, ASND+ND-Lu Xu, 20126469T1753V, A1762T, G1764A, A1762T/G1764A, T1768A, G1862T, G1896A, G1899A, A1762T/G1764A/G1896ARP, AS+-ND-Hangdi Xu2, 2013104254A1846T, G1896ASNP, ASND\-\--*NCA* number of ACLF patients, *NCO* number of CHB patients, *S* sequencing, Apparatus unknown, *NP* nested PCR, *SNP* semi-nested PCR, *RP* routine PCR, *AS* ABI3730XL PRISM sequencing, *SA* Sequence Analysis, *CS* CEQ2000XL sequencing, *DS* direct sequencing, *QPMK* Quickchange point mutation kit, *GC* gene chip hybrid, *UK* unknown, *RFLP* restriction fragment length polymorphism, *MS* MegaBACE DNA sequencing, *MGS* Mgeabace-500 sequencing, *LAS* LicorIR2 Automatic DNA sequencing, *OAS* OpenGene Automated DNA Sequencing, *IS* Illumina sequencing, *ND* not determined, + = matched; - = unmatched; ABI PRISM 3730xl DNA Analyzer

Patient characteristics {#Sec5}
-----------------------

The studies that were included in this meta-analysis compared patients with ACLF and patients with CHB of different severities (mild, moderate and severe), or CHB patients without differentiating by severity. There were mostly males in both the ACLF and CHB groups, and the main genotypes were B and C. There were significantly fewer ACLF HBeAg-positive patients than HBeAg-negative patients, while the opposite was seen in the CHB group (Table [2](#Tab2){ref-type="table"}).Table 2Patient characteristics of included trialsTrialsGroupNAge, yGender (m/f)Genotype (B/O)HBeAg (P/N)TB (μmol/L)HBV DNA (log10IU/ml)Aiming ZhangA2943.427/27/2211/18330.23.86C5242.342/1016/3632/20NG4.63Aiming Zhang2A5847.448/1012/4626/32338.44.02C5146.239/128/4319/32NG4.69Lei XiaoA7738.270/771/622/55427.5NGC13636.9113/2382/5479/5737.62NGXiaodong LiA14647.4119/2730/11645/101313.45C23946.2207/3252/187140/9974.45.8X RenA753967/823/5229/464515.3C32838281/4754/274194/13412.85.2Zhihui XuA29845.9255/4363/23599/199418.55.48C-M/S49538.3/39.1427/6882/413261/23416.4/164.25.26/5.99Ling YangA393636/324/1011/283535.75C442636/822/2236/8NG9.16Zhengang ZhaoA2049.714/60/168/12287.375.82C1940.3714/52/1514/519.757.67Xiaoyan MaA4451.631/130/44NGNGNGC2838.720/82/26NGNGNGZhiwei LiA1321 to 5817/6NGNGNGNGC10NGNGNGNGShoubing TangA302125/5NG13/17NG1.47C302024/6NG16/14NG3.29Yintang JiaA8NGNGNGNGNGNGC78NGNGNGNGNGNGLing JiangA14646119/27NG49/97313.45C-M/S23941/38206/33NG146/9342.38/106.546.27/5.39Wenjun DuA9NGNGNGNGNGNGC75NGNGNGNGNGNGXiumei ZhouA8048.6108/72NGNGNGNGC80NGNGNGNGMingxian ZhouA22NGNG3/19NGNG4.31C56NGNG9/47NGNG4.72Xiaoqiang RenA34846292/5653/200132/216255.94.55C-M/S61038/35518/9295/476386/22412.4/55.44.43/5.21Lei JiangA26NGNGNGNGNGNGC78NGNGNGNGNGNGJinqiang LiA3048.124/6NGNGNGNGC2043.915/5NGNGNGNGChengyong LiuA34NGNGNGNGNGNGC186NGNGNGNGNGNGXinyu LiuA14NGNGNGNGNGNGC75NGNGNGNGNGNGShuren LiangA2339.7118/5NGNGNGNGC-M0/M1/S6835/36.1/35.555/13NGNGNGNGZhidong ZangA17NG10/7NGNG342.32.25C81NG64/17NGNG51.91.83Tao YanA4945.842/79/4023/26312.24.88C4533.936/912/3336/916.56.91Wei GuoA3832.634/4NG21/17NG5.09C4030.233/7NG26/14NG5.48Yanhong YuA25NGNGNGNGNGNGC98NGNGNGNGNGNGGuanghui WuA304025/56/24NGNGNGC302920/104/26NGNGNGHangdi XuA123511/110/24/8324.96.71C1235.710/28/410/215.66.74Fan LiA8745.469/18NG27/603314.42C19638.8170/26NG130/6623.85.42Lu XuA6435.157/7NG31/33372.23.89C6929.548/21NG53/1646.55.49Hangdi Xu2A10440.991/1368/3651/53317.56.09C-M/S25437.6/40.7186/6851/203185/6914.9/98.36.14/5.77*A* ACLF patient group, *C* CHB patient group, *N* number of subjects, *M0* mild, *M1* moderate, *S* severe, *NG* not given, *m/f* male/female, *B/O* genotype B/other genotypes, *TB* Total bilirubin, *HBeAg* hepatitis B e antigen, *P* HBeAg positive, *N* HBeAg negative, *PTA* Prothrombin activity, *ALT* alanine aminotransferase, *AST* Aspertate Aminotransferase

Data synthesis {#Sec6}
--------------

### Overall risk estimates {#Sec7}

The risk assessment for ACLF patients with the mutations of interest in the individual trials is summarized in Additional file [2](#MOESM2){ref-type="media"}: Table S2 and Fig. [2](#Fig2){ref-type="fig"}. Overall, the following mutations were found to be meaningfully related to ACLF risk (shown as summary OR and 95 % \[CI\]): T1753V (1.919 \[1.414--2.606\]), A1762T (2.685 \[2.264--3.185\]), G1764A (2.901 \[2.041--4.122\]), A1762T/G1764A double mutation (2.376 \[1.548--3.648\]), C1766T (1.849 \[1.403--2.437\]), T1768A (2.199 \[1.563--3.094\]), A1846T (3.163 \[2.157--4.639\]), G1896A (2.181 \[1.800--2.642\]), G1899A (3.525 \[2.882--4.312\]) and G1896A/A1762T/G1764A triple mutation (1.575 \[1.172--2.116\]). G1862T was not significantly associated with ACLF risk, but when we removed the study conducted by Xiaoqiang Ren, statistical significance was achieved (summary OR = 2.579 \[1.510--4.405\], *p* = 0.001).Fig. 2Summary odds ratio (OR) of acute-on-chronic liver failure for A1762T, G1764A, A1762T/G1764A and G1896A mutations. *Squares* represent study-specific estimates (size of the square reflects the study-specific statistical weight); *horizontal lines* represent 95 % confidence intervals (CIs); *diamonds* represent summary estimates with corresponding 95 % CIs. Test for heterogeneity: (G1896A) *p* = 0.002, I^2^ = 48.1 %; (A1762T/G1764A) *p* \< 0.001, I^2^ = 80.7 %; (A1762T) *p* = 0.164, I^2^ = 25.7 %; (G1764A) *p* = 0.004, I^2^ = 56.4 %. A random-effects model was used for G1896A, A1762T/G1764A and G1764A, and a fixed-effects model was used for A1762T. All statistical tests were two-sided

### Subgroup analysis {#Sec8}

We evaluated two subgroups, one matched by only patient age and sex, and the other matched by HBV genotype and DNA load, age and sex. The summary OR of ACLF risk for several variations was lower in matched subgroups than that in unmatched subgroups, such as T1753V, A1762T, G1764A, C1766T, G1896A, G1899A and A1846T, while an opposite result was observed for A1762T/G1764A and T1768A (Table [3](#Tab3){ref-type="table"}).Table 3Pooled unadjusted risk estimates of ACLF after stratification or matchingMutation siteMatching factorOR_LCI_UCI*P*T1753Vunmatched1.9191.4142.6060.000age and sex matched1.4810.9822.2340.061age, sex, genotype and HBV DNA matchedNDNDNDNDA1762Tunmatched2.6852.2643.1850.000age and sex matched2.3071.5553.4220.000age, sex, genotype and HBV DNA matched1.3260.5853.0070.499G1764Aunmatched2.9012.0414.1220.000age and sex matched2.0231.0134.0410.046age, sex, genotype and HBV DNA matched1.3100.5553.0940.538A1762T/G1764Aunmatched2.3761.5483.6480.000age and sex matched2.6021.2705.3330.009age, sex, genotype and HBV DNA matchedNDNDNDNDG1896Aunmatched2.1811.8002.6420.000age and sex matched2.0141.5052.6950.000age, sex, genotype and HBV DNA matched1.4791.0172.1520.041G1899Aunmatched3.5252.8824.3120.000age and sex matched3.1712.4644.0810.000age, sex, genotype and HBV DNA matchedNDNDNDNDC1766Tunmatched1.8491.4032.4370.000age and sex matched1.7191.2262.4110.002age, sex, genotype and HBV DNA matchedNDNDNDNDT1768Aunmatched2.1991.5633.0940.000age and sex matched2.2031.4253.4050.000age, sex, genotype and HBV DNA matchedNDNDNDNDA1846Tunmatched3.1632.1574.6390.000age and sex matched2.8542.1273.8310.000age, sex, genotype and HBV DNA matchedNDNDNDND*ND* not determined, *OR* odds ratio, *\_LCI* low limit of 95 % confidence interval, *\_UCI* upper limit of 95 % confidence interval

### Prediction of ACLF by HBV mutation {#Sec9}

We evaluated mutation frequency as a possible biomarker to predict ACLF. Most of the mutation sites showed low sensitivity and relatively high specificity, except A1762T, which had a sensitivity of 74.5 % (95 % CI = 71.9--76.9 %) and specificity of 45.8 % (95 % CI = 43.7--47.9 %). G1764A showed a high positive prediction value (PPV; 80.1 %, 95 % CI, 77.7--82.4; Table [4](#Tab4){ref-type="table"}).Table 4Sensitivity and specificity of single and combined mutations for prediction of ACLFMutation siteMutation statusNo. of ACLF patientsNo. of patients without ACLFSensitivity % (95 % CI)Specificity, % (95 % CI)PPVNPVT1753Vpos39239729.3 (26.9 to 31.9)83.3 (81.8 to 84.8)49.7 (46.1 to 53.2)67.8 (66.0 to 69.5)neg9451986A1762Tpos872120774.5 (71.9 to 76.9)45.8 (43.7 to 47.9)41.9 (39.8 to 44.1)77.3 (75.0 to 80.0)neg2991019G1764Apos92122843.0 (40.9 to 45.1)80.6 (78.3 to 82.9)80.1 (77.7 to 82.4)43.7 (41.6 to 45.9)neg1221949A1762T/G1764Apos67882551.6 (48.9 to 54.4)63.1 (61.1 to 65.1)45.1 (42.6 to 47.7)69.0 (66.9 to 71.0)neg6351412C1766Tpos11311810.3 (8.6 to 12.2)94.1 (93.0 to 95.1)48.9 (42.3 to 55.6)65.8 (64.0 to 67.5)neg9861897T1768Apos80646.9 (5.5 to 8.5)96.9 (96.1 to 97.6)55.6 (47.1 to 63.8)65.1 (63.4 to 66.8)neg10832020A1846Tpos30425154.7 (50.4 to 58.9)72.8 (69.8 to 75.6)54.8 (50.5 to 59.0)72.7 (69.7 to 75.5)neg252670G1896Apos1025125452.6 (50.4 to 54.8)65.6 (64.0 to 67.1)45.0 (42.9 to 47.0)72.1 (70.5 to 73.6)neg9242386G1899Apos32318222.2 (20.1 to 24.4)92.7 (91.7 to 93.7)64.0 (59.6 to 68.2)67.2 (65.6 to 68.8)neg11332325G1896A/A1762T/G1764Apos10713517.6 (14.7 to 20.9)87.4 (85.2 to 89.3)44.2 (37.9 to 50.7)65.1 (62.6 to 67.6)neg500934*Pos* mutation positive, *neg* mutation negative, *PPV* positive predictive value, *NPV* negative predictive value

### HBV genotype and HBeAg status {#Sec10}

The summary OR of HBeAg-negative was 2.813 (95 % CI \[2.240--3.533\], *p* \< 0.001). However, there was no evidence indicating that the HBV genotype B was significantly related to ACLF (Fig. [3](#Fig3){ref-type="fig"}), although we found that this result was unstable using a sensitivity analysis of the following studies: Aiming Zhang, Xiaodong Li, Zhengang Zhao, Xiaoyan Ma, Mingxian Zhou and Tao Yan. When these studies were removed, the summary OR p value was less than 0.05, indicating that more studies were needed to determine the relationship between HBV genotypes and ACLF development.Fig. 3Summary OR of acute-on-chronic liver failure for genotypes and HBeAg status. Summary OR for genotypes B and C and for HBeAg-negative to HBeAg-positive status. *Squares* represent study-specific estimates (the size of the square reflects the study-specific statistical weight); *horizontal lines* represent 95 % CIs; *diamonds* represent summary estimates with corresponding 95 % CIs. Test for heterogeneity: *p* \< 0.001, I^2^ = 79.0 %. A random-effects model was used. All statistical tests were two-sided

Assessment of within-group heterogeneity, publication bias and sensitivity analysis {#Sec11}
-----------------------------------------------------------------------------------

There was a large amount of heterogeneity between different trials for T1753V, G1764A, A1846T, G1862T, G1896A and A1762T/G1764A. We therefore conducted a sensitivity analysis using a "leave one out" approach and Egger's testing, and found that these mutations were not influential, except for G1862T. Except for those with G1764A and G1896A/A1762T/G1764A, we did not observe any publication bias with T1753V, A1762T, A1762T/G1764A, C1766T, T1768A, A1846T, G1862T, G1896A or G1899A, (Table [5](#Tab5){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}).Table 5Assessment of within-group heterogeneity, publication bias and sensitivity analysisMutation site*P* value for heterogeneity*P* value for Egger's testSensitivity analysisT1753V0.0060.923-A1762T0.1640.181-G1764A0.0040.100-A1762T/G1764A0.0000.455-C1766T0.8520.300-T1768A0.6810.291-A1846T0.0370.856-G1862T0.0010.125+G1896A0.0020.520-G1899A0.3070.591-G1896A/A1762T/G1764A0.0730.045-The summary OR did not change statistical significance when running sensitivity analysis. '+' = the *P* value for summary OR reached statistical significance of 0.001 when the trial conducted by Xiaoqiang Ren was removedFig. 4Funnel plot for A1762T, G1764A, A1762T/G1764A and G1896A. The *dashed line* represents 95 % CIs. *Circles* represent individual studies

Discussion {#Sec12}
==========

Our meta-analysis showed that T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899A and G1896A/A1762T/G1764A were all related to increasing the risk of HBV-ACLF by a factor of 1.919, 2.685, 2.901, 2.376, 1.849, 2.199, 3.163, 2.181, 3.525 and 1.575, respectively.

To further confirm these results, several significant confounders were matched. Age and sex have been shown to influence progression of high-level hepatic diseases in CHB patients \[[@CR12]\]. A high HBV DNA copy number may independently accelerate progression of hepatocirrhosis and HCC \[[@CR13], [@CR14]\]. Additionally, compared with genotype B, genotype C was related to more aggressive hepatic necroinflammation, a more rapid rate of progression to cirrhosis and HCC development \[[@CR15]--[@CR17]\], although an association between HBV genotypes B and C and ACLF was not suggested in our study. Most mutations remained significantly associated with ACLF development in age and sex-matched groups and the association with G1896A was still significant after matching age, sex, HBV genotype and HBV DNA load. However, the summary ORs were higher in the confounder-unmatched and age- or sex-only-matched studies than in the age, sex, genotype and DNA load-matched studies. Thus, our results suggest a significant association between HBV variations in BCP/PC regions and the risks of developing ACLF.

The causal relationship between HBV BCP/PC mutations and ACLF development remains unknown. ACLF development was promoted by both acute factors (precipitating events) and chronic factors (underlying chronic liver diseases) \[[@CR18]\]. Previous studies indicated that the role of HBV BCP/PC mutations that promote ACLF were more likely to influence the severity of chronic factors, because the mutations were detected both in CHB and HBV-ACLF patients. It was also reported that HBV BCP/PC variations appeared less frequently in CHB patients than in cirrhotic patients \[[@CR19], [@CR20]\], suggesting a process where mutations accumulate during CHB infection and are associated with late-stage viral infection. Thus, these results suggested that patients with BCP/PC mutations had more advanced HBV-related chronic liver diseases, and thus were more susceptible to hepatic insult and more likely to develop ACLF. Accumulating evidence suggests that mutations in the BCP/PC region might exacerbate liver injury by affecting HBeAg expression and/or viral replication, which may in turn affect the immune response to HBV \[[@CR21]\]. For example, Yang et al. suggested that HBeAg expression in the perinatal infection period caused immune tolerance \[[@CR22]\]. Another characteristic of HBeAg that might accelerate chronic infection is that it may imitate the core protein to weaken the immune response caused by antibodies in infected hepatocytes \[[@CR10]\]. When the occurrence of HBV mutants in different phenotypes disturbs the balance, the altered virus--cell relationship might activate adverse immune responses in some patients, causing massive hepatocyte necrosis.

When exploring the potential value of HBV variation in predicting HBV-ACLF, we found that T1753V, G1764A, C1766T, T1768A, G1899A and G1896A/A1762T/G1764A triple mutations were useful in predicting ACLF. A combination of A1762T/G1764A and G1896A showed a higher specificity than A1762T/G1764A double mutations (Table [4](#Tab4){ref-type="table"}), suggesting that mutations that accumulate at different sites have synergistic effects in promoting the risk of HBV-ACLF. The results indicated that the above HBV mutations may be used as biomarkers for supporting the development of HBV-associated ACLF.

Our study also showed the relationship between HBeAg-negative status and the risk of ACLF using a pooled OR = 2.813, *p* \< 0.001. However this relationship was probably not independent. In G1896A patients, the concentration of serum toll-like receptor 2 (TLR2) reached a significantly higher level than in HBV-infected patients lacking G1896A \[[@CR23]\]. In the absence of HBeAg, HBV up-regulated TLR2 expression on CD14+ cells \[[@CR24]\]. TLR2 is a potential connection between G1896A and HBeAg-negative status.

This study had several limitations. First, all trials were observational so that unidentified confounders could not be eliminated. Second, because we searched only Chinese and English articles, selection bias based on language could not be avoided. Third, the data was insufficient to allow analysis of mutations such as G1896A/G1899A, G1896A/G1899A/A1762T/G1764A and C1913V that were implicated in ACLF development in some studies \[[@CR25]--[@CR31]\]. Additionally, HBV mutations in other regions were not analyzed in the study. For example, pre-S/S region mutations were observed at an advanced stage of chronic HBV infection \[[@CR32], [@CR33]\]. The pre-S deletion mutation has been reported to increase with liver disease progression \[[@CR34]\]. In addition, pre-S/S region mutations could alter the immune response against HBV by affecting neutralization antibody epitopes \[[@CR35]\] or cytotoxic T lymphocyte epitope binding affinity \[[@CR36]\]. Thus, ongoing studies are needed to evaluate the clinical relevance of rare mutations in the BCP region and mutations in other regions. Fourth, the conclusions in this article might not be universally applicable, because all the selected trials were conducted in China. Although no study has reported a direct relationship between the risk of ACLF and country or race, the distribution of HBV genotypes or quasispecies differs among countries and races. For example, the most prevalent HBV genotypes in China are B and C, whereas genotypes A and D are the most prevalent in Europe \[[@CR37]\]. Although our analysis did not show a different association between genotype B or C and ACLF risk, it is unknown whether there was a different connection between other HBV genotypes and ACLF. Thus, this conclusion needs to be validated for countries or races where other HBV genotypes are the most prevalent. Fifth, summary ORs were not conducted in most manuscripts included in this meta-analysis and there were no adjusted ORs. Sixth, if the sample size were sufficiently large, grouping the HBV patients based on grades, such as HBV carriers, CHB and hepatocirrhosis, would show whether the mutations accumulated during CHB progressed to advanced liver diseases, including ACLF.

We discovered that HBV BCP/PC variations such as T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1896A, G1899A and G1896A/A1762T/G1764A, and HBeAg-negative status correlated with an increased risk of HBV-ACLF. Detecting these variations in CHB patients may help to identify those who are at a high risk of developing ACLF. However, further prospective studies are needed to confirm our findings and whether HBV BCP/PC mutations contribute directly to the development of ACLF. The effect of HBV BCP/PC mutations on host viral-specific immunity also needs to be clarified.

Conclusions {#Sec13}
===========

The HBV BCP/PC mutations T1753V, A1762T, G1764A, C1766T, T1768A, A1846T, G1896A and G1899A, and an HBeAg-negative status correlate with an increased risk of HBV-ACLF.

Methods {#Sec14}
=======

Search strategy and inclusion/exclusion criteria {#Sec15}
------------------------------------------------

We searched PubMed using the following strategy: ("Hepatitis B virus" \[Mesh\]) AND "mutation" \[Mesh\] from January 1, 1950 to January 31, 2014. The search strategy for EMbase was "pub-date \> 1994 and TITLE-ABSTR-KEY (hepatitis B virus), and TITLE-ABSTR-KEY (mutation)". Biomed Central was searched using "hepatitis B virus (All words) in Title + Abstract + Text, and mutation (All words) in Title + Abstract + Text from 1997 to 2014". ClinicalTrials was searched with "hepatitis B virus" AND "mutation" without limitation. The main Chinese databases were searched using: Chinese Biological Medicine (1978 to January 31, 2014), WANFANG DATA (1997 to January 31, 2014), VIP (1989 to January 31, 2014), China National Knowledge Infrastructure (1994 to January 31, 2014); the search strategy was "hepatitis B" \[Abstract\] AND "mutation" \[Abstract\]. The inclusion criteria were: 1) studies contained control groups; 2) ACLF diagnosis was based on the APASL criteria, as follows: serum bilirubin ≥5 mg/dl and coagulopathy (INR ≥ 1.5 or PTA \< 40 %) are mandatory. Ascites and/or encephalopathy were determined by physical examination within 4 weeks \[[@CR38]\], or the ACLF diagnosis was based on the criteria recommended by the Chinese Society of Infectious Disease and the Chinese Society of Hepatology: HBV infection history; total serum bilirubin \>10 mg/dl, PTA \< 40 % and recent complications that also meet APASL criteria; 3) BCP or PC mutations were detected; 4) the outcome was ACLF; and 5) ORs and 95 % CIs were shown or could be calculated from original data. Studies without control groups or studies in which patients were co-infected with another hepatitis virus or HIV, with the presence of other underlying chronic liver diseases (such as Wilson disease and autoimmune hepatitis) or liver cancer were excluded. For studies that contained over-lapping populations, the study containing the larger number of participants or the most recent study was included.

Data extraction {#Sec16}
---------------

Feishu Hu and Sheng Bi extracted information independently as follows: publication year, location, study design, number and subject characteristics, HBV mutations, genotypes, HBeAg status, variation testing approach and probable confounding factors. All authors discussed results and reached an agreement if there were discrepancies. BCP/PC region mutation sites were included. Patients co-infected with wild-type viruses and BCP/PC mutated viruses were excluded. Subjects with a single mutation were excluded when assessing A1762T/G1764A double mutations and A1762T/G1764A/G1896A triple mutations.

Study quality assessment {#Sec17}
------------------------

Feishu Hu and Sheng Bi independently evaluated the quality of trials using the NOS, which was developed for case--control studies. Each study that was included was judged on three broad perspectives: selection of study groups, comparability of groups and ascertainment of exposure for case--control studies. Disagreements were resolved by discussion between all authors.

Statistical analysis {#Sec18}
--------------------

The effect measures were ORs and the corresponding 95 % CIs. Within-study heterogeneity was assessed using Cochrane's Q-test and the I^2^ test \[[@CR39]\]. Summary ORs were pooled by a random or fixed-effect model based on the results of a heterogeneity test. To detect the stability with primary analysis, we conducted a sensitivity analysis using a "leave one out analysis". Publication bias was detected using funnel plots and the Egger test \[[@CR40]\]. Significant publication bias was believed to be present if a p value was less than 0.1. We also conducted subgroup analysis by stratifying the study participants according to probable confounders such as sex, age, HBV DNA and HBV genotype and we calculated the respective summary risk estimates. We used Stata software (version 12.0; Stata Corp, College Station, TX) to conduct the analysis and to calculate the ACLF summary estimates for the HBV genotype, HBeAg status and T1753V, A1762T, G1764A, A1762T/G1764A, C1766T, T1768A, A1846T, G1862T, G1896A, G1899A and A1762T/G1764A/G1896A mutations for ACLF patients. The following mutation sites were also detected in the included studies: G1613A, C1653T, 1752G, T1754V, T1753V/A1762T/G1764A, T1758C, G1764A/C1766T/T1768A, T1770A, 1773 T, G1775A, C1799V, T1800C, T1803C, G1809T, A1814C, A1837G, A1846G, T1853C, T1858C, G1896A/G1899A, G1896A/G1899A/A1762T/G1764A, C1913V, 1915A/C, T1938C, A1979G, T1961V and T1753V/A1762T/G1764A/G1896A/G1899A, but they were not included in this meta-analysis because the data was insufficient. Variation frequency between CHB patients and HBV-ACLF patients was compared using the Chi-squared test. Sensitivity and specificity of HBV mutations for ACLF was evaluated to indicate the possibility of using certain mutations to predict the development of HBV-ACLF.

Additional files {#Sec19}
================

Additional file 1: Table S1.The Newcastle-Ottawa Scale (NOS) for assessing the quality of the included studies.Additional file 2: Table S2.Pooled unadjusted risk estimates of ACLF of specific mutation sites.
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